Rheumatology
Conference Coverage
FAST trial clears febuxostat of increased mortality in gout
Researchers in Europe compare adverse cardiovascular events, including mortality, between febuxostat and allopurinol among older adults with gout...
Conference Coverage
Denosumab favored over alendronate for BMD protection in glucocorticoid-induced osteoporosis
Denosumab “may be considered as an alternative first-line therapy in higher-risk patients and in those who are contraindicated for the oral...
Conference Coverage
COVID-19 risks in rheumatic disease remain unclear
Elevated COVID-19-related risks, many associated with comorbidities, emerged in a match-control study, whereas a systematic review delivers more...
Conference Coverage
COVID-19–related HCQ shortages affected rheumatology patients worldwide
Data from the Global Rheumatology Alliance Patient Experience Survey presented at ACR Convergence 2020 demonstrate that the severity of shortages...
News
Decline in febuxostat use trends with cardiovascular concerns
Prescriptions of urate-lowering therapy remain steady, but febuxostat lost favor in the wake of a black-box warning from the Food and Drug...
Conference Coverage
Dr. Brian Mandell gives his take on ACR’s newest gout guideline
New guideline articulates a broad approach to treatment that needs to be tailored to individual patients.
News
Role of aspirin explored in primary prevention of CVD in systemic rheumatic diseases
“The message for rheumatologists is it needs to be prescribed on an individual basis, rather than based on diagnosis of a rheumatic condition – at...
Conference Coverage
Treat-to-target strategy ‘not ready for primetime’ in osteoporosis
Debaters at a session of the recent virtual ASBMR 2020 annual meeting could have gone either way on this topic, but data and evidence are...
News
Diffuse idiopathic skeletal hyperostosis heart risk higher than expected
Cardiovascular disease, most notably myocardial infarction, occurs in more people with DISH than is predicted by the Framingham Risk Score.
News
COVID-19 outcomes no worse in patients on TNF inhibitors or methotrexate
No increase was seen in hospitalization and death rates, providing additional support for keeping patients on these immunosuppressive treatments...